FOR IMMEDIATE RELEASE:
March 24, 2009
Statement of the American Cancer Society Cancer Action Network, American Heart Association, Campaign for Tobacco-Free Kids and the American Lung Association
Washington, D.C. (March 24, 2009) – The American Cancer Society Cancer Action Network, the American Heart Association, the American Lung Association and the Campaign for Tobacco-Free Kids applaud Senator Frank Lautenberg of New Jersey’s call for the Food and Drug Administration to exert its authority and immediately remove e-cigarettes from the market.
FDA officials have been quoted numerous times in many publications during the past few weeks saying that e-cigarettes are “new drugs,” which require prior approval from the FDA before they are allowed to be sold. Without this approval, e-cigarettes are illegal to market or sell. Despite these statements, no action has been taken to remove e-cigarettes from the market.
Currently, e-cigarettes are being sold in 62 kiosks at malls across the United States, with plans to expand to another 55. E-cigarettes are also being marketed towards young people, who can purchase them in fruit flavors and online, without having to verify their ages.
State Settlement Report
A Broken Promise to Our Children: The 1998 State Tobacco Settlement Eight Years Later
Smoke-Free Workplace Laws
Protect Our Right to Breathe Clean Air
obacco use takes a huge toll in health, lives and money on every state in the nation. Tobacco-related health care bills cost the states and taxpayers billions of dollars each year under Medicaid and other state-funded health care programs. The good news is that state and local governments can reduce tobacco use, save lives and save money by implementing proven solutions to the problem. The solutions include:
Well-funded tobacco prevention and cessation programs:
The states collect nearly $25 billion a year in tobacco-generated
revenue from tobacco taxes and the 1998 state tobacco settlement. Less
than three percent of this tobacco money would be enough to fund
tobacco prevention and cessation programs in every state at levels
recommended by the U.S. Centers for Disease Control and Prevention
(CDC). Unfortunately, no state currently funds prevention programs at
CDC-recommended levels, and only nine states provide even half the
Learn more from our annual report, A Decade of Broken Promises: The 1998 State Tobacco Settlement Ten Years Later.
Contact: Joel Spivak, (202)296-5469
September 30, 2009
Eleven Health & Consumer Groups Urge Federal Court to Reject Tobacco Companies' Lawsuit Against FDA Tobacco Regulation Law
Washington, D.C. - Today, eleven public health and consumer advocacy organizations filed a friend of the court (amicus) brief asking a federal court to reject a lawsuit by R.J. Reynolds, Lorillard and other tobacco companies that seeks to block key provisions of the new federal law regulating tobacco products. The immediate issue before the court is the industry's challenge of a provision that requires FDA approval before tobacco companies can make claims about "modified risk tobacco products."
The tobacco companies have also challenged other marketing restrictions in the Family Smoking Prevention and Tobacco Control Act, which authorizes the U.S. Food and Drug Administration (FDA) to regulate the manufacturing, marketing and sale of tobacco products.
CDC’s Office on Smoking and Health (OSH) created the National Tobacco Control Program (NTCP) in 1999 to encourage coordinated, national efforts to reduce tobacco-related diseases and deaths. The program provides funding and technical support to state and territorial health departments. NTCP funds
NTCP-funded programs are working to achieve the objectives outlined in OSH’s Best Practices for Comprehensive Tobacco Control Programs.
The four goals of NTCP are to
The four components of NTCP are
As part of the recently enacted Family Smoking Prevention and Tobacco Control Act
, the FDA regulation of tobacco products immediately removes most federal pre-emption constraints on the ability of states and communities to restrict the time, manner, and place of tobacco advertising and promotions.
For questions regarding potential actions that may have been pre-empted previously, or could still be pre-empted even in the context of this new legislation, please send an e-mail to FDAQuestions@cdc.gov.
Questions received through this e-mail box will be used to support FDA in issuing appropriate rules and guidance but may not be answered individually.
Creation of the National Cancer Fund
In 2008, ACS CAN strongly supported legislation introduced in the House of Representatives to create a National Cancer Fund to pay for new research to find prevention and early detection tools for the most deadly cancers, to fully fund nationwide breast and cervical and colorectal cancer screening and treatment programs, to expand access to clinical trials and to undertake other important nationwide initiatives in the war on cancer. The legislation would raise $7 billion annually through an increase in the federal tobacco tax as a dedicated source of funding for the Fund. A nationwide survey conducted in April 2008 by Lake Research Partners found overwhelming public support for the legislation. 87 percent supported creation of a special cancer fund, and 60 percent said they would be more likely to support an elected official for re-election if the official voted to create the Fund. Given the nearly flat funding for cancer research and control programs over the past five years, ACS CAN strongly believes there is a need and justification for a dedicated source of federal funds for cancer and will strongly advocate in support of the National Cancer Fund legislation in 2009.
Funding for both NIH and NCI has been nearly flat since 2003. The result of this trend is that NCI funding is currently 16.2 percent below the 2003 level, when we adjusted for biomedical inflation. Unless we reverse the trend of level funding for NIH and NCI, we risk stalling the progress we have made in recent years. To reverse this trend ACS CAN supports substantial increases for NIH and NCI that exceed the rate of biomedical inflation for FY10.
Continue ... to learn more about the 2009 Federal Priorities
Hundreds of Cancer Advocates to Urge Lawmakers to Put Patients Before Politics
Rep. Waxman, Florida State Sen. Deutch and North Carolina State Rep. Holliman to be Honored For Leadership in the Fight Against Cancer
WASHINGTON -- September 21, 2009 -- More than 400 cancer patients, survivors, caregivers and their families from all 50 states and nearly every Congressional district will unite tomorrow to lobby their members of Congress in support of comprehensive health care reform. The American Cancer Society Cancer Action Network (ACS CAN) is hosting its annual leadership summit and lobby day to urge lawmakers to focus on patients, not politics, by supporting reform that escalates the emphasis on disease prevention and ensures that all Americans have access to health care.
Canada's Federal Tobacco Control Strategy (FTCS) is championed by many parties working towards a common goal: reducing tobacco use. The FTCS was implemented in April 2001, and is backed by a major investment of $560 million divided among five federal departments over five years (of which $480 million funds Health Canada initiatives).More Information
Every 11 minutes, a
Canadian dies from tobacco use. Every 10 minutes, two Canadian
teenagers start smoking cigarettes; one of them will lose her life
because of it. Yearly, more than a thousand Canadians who never even
smoked die - from exposure to tobacco smoke. Thousands more are
diagnosed with illnesses related to tobacco use. Year in and year out,
more than 37,000 Canadians perish - because of tobacco.
That's more than five times the number of Canadians who die from traffic injuries, alcohol abuse, murder and suicide combined. And yet ... tobacco use is the single most preventable cause of premature death and disease in Canada.
Canada has made more progress in tobacco control in recent years than have most other countries in the world. Few countries have seen such a dramatic decline in consumption. Few have seen a decline in the prevalence of tobacco use as significant and sustained as we have in Canada. Few have seen such a pervasive shift in attitudes towards tobacco. And few countries in the world today have launched such a comprehensive drive towards a reduction in smoking prevalence. Now, many countries are modelling their efforts on Canada's Federal Tobacco Control Strategy.
Clearly there is tremendous progress. Nevertheless, challenges remain. Find out what's going on in tobacco control in Canada, and who does what.Continued
Health Canada plays an active role in ensuring that you have access to safe and effective drugs and health products. The Department strives to maintain a balance between the potential health benefits and risks posed by all drugs and health products. Our highest priority in determining the balance is public safety.
Working together with other levels of government, health care professionals, patient and consumer interest groups, research communities and manufacturers, our department endeavours to minimize the health risk factors to you and maximize the safety provided by the regulatory system for these products.
We also strive to provide you with the information you need to make healthy choices and informed decisions about your health.
Health Canada is not a manufacturer or distributor of drugs and health products. We are the federal regulator. For additional drug information related to treatment options or where drugs or health products are sold, please contact your health professional or the individual company directly.
Health Canada is committed to providing timely access to sound, evidence-based information. We want to ensure that Canadians remain up-to-date on current developments and issues pertaining to drugs and health products in Canada.
The Progressive Licensing Project has been initiated to develop a drug regulatory system for the future, and gives details of the plan for developing a new framework, and provides an opportunity for discussion with Canadians regarding drug licensing.
Access to Therapeutic Products: The Regulatory Process in Canada. This publication describes how therapeutic products in Canada make their way from the laboratory to the marketplace.
Find more information about biotechnology-based health products in the Science and Research section of our Web site.
New Applicants: No further applications will be accepted.
Current Grantees: Awarded research will continue as scheduled. Please consult the current contacts list for all the inquires.
|Research Grant Program
|Idea Grant to encourage unique or original research that has the potential to advance knowledge in tobacco control||Up to $50,000 for one year|
Policy Research Grant (regular stream) to stimulate research that will influence, guide or have a direct impact on policy decisions in tobacco control
Up to $80,000 total for research to be completed within two years
|Policy Research Grant (Fast Track) to stimulate research that will influence, guide or have a direct impact on policy decisions in tobacco control||Up to $80,000 total for research to be completed within one years|
Knowledge Synthesis Grant to support interdisciplinary teams of researchers and practioners/decision-makers to conduct collaborative reviews of evidence for particular tobacco control interventions
|Up to $120,000 for one year|
|Research Planning Grant to bring together new, multi-sectoral and interdisciplinary research teams to construct research proposals for submission to traditional open funding competitions||Up to $15,000 for one year|
Researcher Travel Grant to provide opportunities for graduate and post-doctoral students and individuals affiliated with non-governmental organizations/community groups to attend conferences/meetings related to tobacco abuse and nicotine addiction
|Up to $3,000
|Student Research Grant to provide opportunities for graduate and post-doctoral students to undertake tobacco abuse and nicotine addiction research||Up to $10,000 for one year|
|Workshop and Learning Opportunities Grant to support workshops, meetings and other events to build research capacity||Up to $15,000|
These grant programs were administered by the CTCRI and funded in a partnership with:
The CTCRI congratulates all successful applicants of the recent competitions!
Scientific Review Panel:
Tony George, Centre for Addiction and Mental Health
"A nicotinic partial agonist for tobacco dependence treatment in bipolar disorder"
Robert Schwartz, University of Toronto, Ontario Tobacco Research Unit
“Cigarette pack as advertisement: Beyond light and mild”
John Church, University Alberta
"Understanding Canadian tobacco control policy through provincial policy network analysis"
Lorraine Greaves, British Columbia Centre of Excellence for Women's Health
"Social and built environments and gendered effects of secondhand smoke (SHS) policies"
Robert Schwartz, University of Toronto, Ontario Tobacco Research Unit
"Cigarillo use among young adults: An assessment of the impact of restrictions on cigarillo sales"
Annette Schultz, University of Manitoba
“Exploring the shifting culture surrounding tobacco use on in-patient psychiatric units post-implementation of smoke-free hospital grounds policies”
Paul Clarke, McGill University
“In quest of non-nicotinic reinforcing substances in tobacco smoke”
Benita Cohen, University of Manitoba
“Exploring issues of equity within Canadian tobacco control initiatives: An environmental scan”
Bernard Le Foll, Centre for Addiction and Mental Health
“Testing the Gabaergic hypothesis of nicotine dependence: a randomized clinical trial of baclofen”
Kathryn Hyndman, Brandon University
“A survey of health professionals' training in tobacco reduction counselling on the Canadian prairies"
Sean Barrett, Dalhousie University
“Tobacco Control in Nova Scotia: Developing Best Practices for Implementing and Monitoring Smoking Cessation Programs"
William Callery, University of Waterloo
"Impact of health warning messages on smokeless tobacco products"
Juliana Doxey, University of Waterloo
“The impact of cigarette packaging on young women: Brand appeal, beliefs about smoking, and risk perception”
Laura McCammon-Trip, University of Waterloo
“The impact of drifting environmental tobacco smoke in multi-unit dwellings: Measurements and perceptions”
Yijin Yan, Centre for Addiction and Mental Health
“Role of dopamine D4 receptor in nicotine self-administration and reinstatement”
14th World Conference on Tobacco or Health – Mumbai, India
Michael Cantinotti, CSSS-Vieille-Capitale, CAU
“Smoking and Second-hand Smoke among Prison Employees: It's Time to Act !”